The dominance of interferon- and NF-κB–driven programs aligns with the slower tumor progression observed in KO mice, implying that CD301b deficiency reprograms the TME toward a functionally immune-active, tumor-controlling state. The gene discussed is NFKB1; the disease is neoplasm.